Skip to main content
Can-Fite BioPharma Ltd. logo

Can-Fite BioPharma Ltd. — Investor Relations & Filings

Ticker · CANF ISIN · IL0010944739 LEI · 549300ZLRH6GSBOHFZ59 TA Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2026-03-11 Declaration of Voting R…
Country IL Israel
Listing TA CANF

About Can-Fite BioPharma Ltd.

https://www.canfite.com/

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company with integrated drug discovery and development capabilities. The company specializes in creating orally bioavailable small-molecule drugs. Its proprietary platform technology is centered on the A3 adenosine receptor (A3AR), a therapeutic target highly expressed in cancer and inflammatory cells but minimally in normal cells. Can-Fite's compounds bind to A3AR to initiate anti-cancer and anti-inflammatory effects by modulating cellular signal transduction pathways. The company's advanced pipeline features proprietary drug candidates in Phase II and Phase III clinical development for treating oncology, inflammatory, liver, and metabolic diseases. A lead drug, Namodenoson, is in a pivotal Phase III study for advanced liver cancer.

Recent filings

Filing Released Lang Actions
Other Report or Announcement
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a Form 6-K filed with the SEC, which reports the results of a Special General Meeting of Shareholders held on March 10, 2026. It explicitly states that the shareholders approved the proposals brought before them. Since this document serves as the official notification of the outcome of a shareholder vote, it falls under the category of Declaration of Voting Results.
2026-03-11 English
Other Report or Announcement
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short regulatory filing from Can-Fite Biopharma Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on Shareholders meeting results' and provides a reference to an attached PDF. According to the 'Menu vs Meal' rule, since this is a short announcement document indicating that the actual report (the results of the meeting) is attached, it is classified as a Declaration of Voting Results & Voting Rights Announcement (DVA) as it pertains to the official results of a shareholder meeting.
2026-03-11 English
424b3 Prospectus supplement
Capital/Financing Update Classification · 1% confidence The document is a Form 424B3, which is a prospectus supplement filed with the SEC. It details a securities offering involving the exercise of existing warrants and the issuance of new warrants, including terms of the inducement offer, placement agent details, and capital structure implications. While it incorporates a Form 6-K, the primary nature of the filing is a capital/financing update regarding the company's securities and warrant structure.
2026-03-05 English
424b3 Prospectus supplement
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing from Can-Fite BioPharma Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on 424b3 Prospectus supplement' and provides a filename for the attachment. Per the 'Menu vs Meal' rule, since this is a short announcement notifying the public of an attached report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2026-03-05 English
6K-Exercise of Warrants, expects to receive aggregate gross proceeds of approximately $4.0 million
Capital/Financing Update Classification · 1% confidence The document is a Form 6-K filed by Can-Fite Biopharma Ltd. with the SEC. It details an inducement offer letter agreement regarding the exercise of existing warrants and the issuance of new warrants, which constitutes a capital financing activity. While it includes a press release as an exhibit, the core of the filing is the disclosure of the financing transaction terms, making it a Capital/Financing Update.
2026-03-05 English
6K-Exercise of Warrants, expects to receive aggregate gross proceeds of approximately $4.0 million
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing from Can-Fite Biopharma Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on Warrant inducement' and provides a reference to an external PDF file. Following the 'Menu vs Meal' rule, since the document is a short announcement (under 5,000 characters) notifying the public of an attached report, it is classified as a Report Publication Announcement (RPA).
2026-03-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.